TEMPO Extentension Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients
Links shared publicly online about this topic.
- 967total visits
TEMPO Extentension Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients
View full resource at medicalnewstoday.com
Tags: Parkinson's Disease, Disease and Condition, Pharma, Teva Pharmaceutical Industries
Most Recently Shared on August 7, 2010 at 4:46 pm By:
TEMPO Extentension Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients: Tev... http://bit.ly/dsQTLu
Also Shared By:
TEMPO Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients
medicalnewstoday.com — “H. Lundbeck A/S (Lundbeck) and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-” View full resource at medicalnewstoday.com
Most Recently Shared on August 9, 2010 at 2:00 pm By:
MNT Parkinson's News Health News
TEMPO Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients http://mnt.to/3H8W #parkinsons
TEMPO Extension Study Further Demonstrates the Benefits of Azilect in Early Parkinson's Disease Patients - Drugs.com MedNews
drugs.com — “Newly Published Data Confirms Long Term Efficacy, Safety and Tolerability in Treating Early Parkinson s Disease Aug 5, 2010 - Teva Pharmaceutical Industries Ltd” View full resource at drugs.com
Most Recently Shared on August 6, 2010 at 6:45 pm By:
TEMPO Extension Study Further Demonstrates the Benefits of Azilect in Early Parkinson's Disease Patients: -- Newly... http://bit.ly/9XN8d6
TEMPO study added support for Azilect in PD patients
news-medical.net — “Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.” View full resource at news-medical.net
Most Recently Shared on August 6, 2010 at 6:25 am By:
Parkinson's Disease: TEMPO study added support for Azilect in PD patients: Teva Pharmaceutical Industries Ltd. and... http://bit.ly/af7fuX
Advertisement
MNT Parkinson's News
@mnt_parkinsons
TEMPO Study Further Demonstrates The Benefits Of Azilect® In Early Parkinson's Disease Patients http://mnt.to/3H8W #parkinsons
1 year ago...